Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Laurent Roberto Chiarelli

Associate Professor

Università degli Studi di Pavia

Italy

Has grant

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacology

50%

Pharmaceutical Chemistry

20%

Antimicrobial Research

70%

Antibiotic Therapy

40%

Molecular Docking

30%

Drug Formulation

30%

Chemical Biology

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Recent Grants

Grant: Close

Nontuberculous mycobacteria in cystic fibrosis: scouting molecules against M. abscessus iron acquisition pathways

Open Date: 2022-09-01

Close Date: 2024-08-01

Articles24

Synthesis, structural characterization, and biological evaluation of cinnamaldehyde–azomethine hybrids: In Vitro and In Silico approaches

Article Link

Year:

2026

Repurposing of FDA‐Approved Drugs to Disrupt Iron Uptake in Mycobacterium abscessus: Targeting Salicylate Synthase as a Novel Approach

Article Link

Year:

2025

Artificial Intuition and accelerating the process of antimicrobial drug discovery

Article Link

Year:

2025

Artificial Intuition and accelerating the process of antimicrobial drug discovery

Article Link

Year:

2025

Mycobacterium tuberculosis Sulfate Ester Dioxygenase Rv3406 Is Able to Inactivate the RCB18350 Compound.

Article Link

Year:

2025

Nanoenabling MbtI Inhibitors for Next-Generation Tuberculosis Therapy

Article Link

Year:

2025

The novel drug candidate VOMG kills Mycobacterium abscessus and other pathogens by inhibiting cell division

Article Link

Year:

2024

Phage Therapy: An Alternative Approach to Combating Multidrug-Resistant Bacterial Infections in Cystic Fibrosis

Article Link

Year:

2024

Benzothiozinone derivatives with anti-tubercular Activity-Further side chain investigation

Article Link

Year:

2024

Editorial: Enzyme targeting for the development of novel antimicrobials

Article Link

Year:

2024

Structural basis for specific inhibition of salicylate synthase from Mycobacterium abscessus

Article Link

Year:

2024

Could the Oxidation of α1-Antitrypsin Prevent the Binding of Human Neutrophil Elastase in COVID-19 Patients?

Article Link

Year:

2023

CanB, a Druggable Cellular Target in Mycobacterium tuberculosis

Article Link

Year:

2023

CanB, a Druggable Cellular Target in Mycobacterium tuberculosis

Article Link

Year:

2023

Improving Protection to Prevent Bacterial Infections: Preliminary Applications of Reverse Vaccinology against the Main Cystic Fibrosis Pathogens

Article Link

Year:

2023

Side Chain-Modified Benzothiazinone Derivatives with Anti-Mycobacterial Activity

Article Link

Year:

2023

Iron Acquisition and Metabolism as a Promising Target for Antimicrobials (Bottlenecks and Opportunities): Where Do We Stand?

Article Link

Year:

2023

Iron Acquisition and Metabolism as a Promising Target for Antimicrobials (Bottlenecks and Opportunities): Where Do We Stand?

Article Link

Year:

2023

Mycobacterium abscessus Infections in Cystic Fibrosis Individuals: A Review on Therapeutic Options

Article Link

Year:

2023

Mycobacterium abscessus Infections in Cystic Fibrosis Individuals: A Review on Therapeutic Options

Article Link

Year:

2023

Targeting Siderophore-Mediated Iron Uptake in M. abscessus: A New Strategy to Limit the Virulence of Non-Tuberculous Mycobacteria

Article Link

Year:

2023

Structural Study of a New MbtI-Inhibitor Complex: Towards an Optimized Model for Structure-Based Drug Discovery

Article Link

Year:

2023

Structural Study of a New MbtI-Inhibitor Complex: Towards an Optimized Model for Structure-Based Drug Discovery

Article Link

Year:

2023

Could the Oxidation of a1-Antitrypsin Prevent the Binding of Human Neutrophil Elastase in COVID-19 Patients?

Article Link

Year:

2023

Collaborators11

Maria Rosalia PASCA

Professore Ordinario BIO/19

Università degli Studi di Pavia

ITALY

GIAMPIERO PIETROCOLA

University of Pavia

ITALY

Stefania Villa

ITALY

Fabrizio Manetti

Professor of Medicinal Chemistry

University of Siena

ITALY

Fiorella Meneghetti

University of Milan

ITALY

Giovanni Stelitano

University of Pavia

ITALY

Giulia Degiacomi

University of Pavia

ITALY

Simona Viglio

University of Pavia

ITALY

Silvia Buroni

Associate Professor

Università degli Studi di Pavia

ITALY

Arianna Gelain

University of Milan

ITALY

Simona Collina

University of Pavia

ITALY

How do I reach out?

Meet Kite AI

Laurent Roberto Chiarelli

Associate Professor

How do I reach out?

Contact this professor

Research Interests

Ask ApplyKite AI

Recent Grants

Articles24

Synthesis, structural characterization, and biological evaluation of cinnamaldehyde–azomethine hybrids: In Vitro and In Silico approaches

Repurposing of FDA‐Approved Drugs to Disrupt Iron Uptake in Mycobacterium abscessus: Targeting Salicylate Synthase as a Novel Approach

Artificial Intuition and accelerating the process of antimicrobial drug discovery

Artificial Intuition and accelerating the process of antimicrobial drug discovery

&lt;i&gt;Mycobacterium tuberculosis&lt;/i&gt; Sulfate Ester Dioxygenase Rv3406 Is Able to Inactivate the RCB18350 Compound.

Nanoenabling MbtI Inhibitors for Next-Generation Tuberculosis Therapy

The novel drug candidate VOMG kills Mycobacterium abscessus and other pathogens by inhibiting cell division

Phage Therapy: An Alternative Approach to Combating Multidrug-Resistant Bacterial Infections in Cystic Fibrosis

Benzothiozinone derivatives with anti-tubercular Activity-Further side chain investigation

Editorial: Enzyme targeting for the development of novel antimicrobials

Structural basis for specific inhibition of salicylate synthase from <i>Mycobacterium abs</i>cessus

Could the Oxidation of α1-Antitrypsin Prevent the Binding of Human Neutrophil Elastase in COVID-19 Patients?

CanB, a Druggable Cellular Target in Mycobacterium tuberculosis

CanB, a Druggable Cellular Target in Mycobacterium tuberculosis

Improving Protection to Prevent Bacterial Infections: Preliminary Applications of Reverse Vaccinology against the Main Cystic Fibrosis Pathogens

Side Chain-Modified Benzothiazinone Derivatives with Anti-Mycobacterial Activity

Iron Acquisition and Metabolism as a Promising Target for Antimicrobials (Bottlenecks and Opportunities): Where Do We Stand?

Iron Acquisition and Metabolism as a Promising Target for Antimicrobials (Bottlenecks and Opportunities): Where Do We Stand?

Mycobacterium abscessus Infections in Cystic Fibrosis Individuals: A Review on Therapeutic Options

Mycobacterium abscessus Infections in Cystic Fibrosis Individuals: A Review on Therapeutic Options

Targeting Siderophore-Mediated Iron Uptake in <i>M. abscessus</i>: A New Strategy to Limit the Virulence of Non-Tuberculous Mycobacteria

Structural Study of a New MbtI-Inhibitor Complex: Towards an Optimized Model for Structure-Based Drug Discovery

Structural Study of a New MbtI-Inhibitor Complex: Towards an Optimized Model for Structure-Based Drug Discovery

Could the Oxidation of a1-Antitrypsin Prevent the Binding of Human Neutrophil Elastase in COVID-19 Patients?

Collaborators11

Maria Rosalia PASCA

GIAMPIERO PIETROCOLA

Stefania Villa

Fabrizio Manetti

Fiorella Meneghetti

Giovanni Stelitano

Giulia Degiacomi

Simona Viglio

Silvia Buroni

Arianna Gelain

Simona Collina

How do I reach out?

<i>Mycobacterium tuberculosis</i> Sulfate Ester Dioxygenase Rv3406 Is Able to Inactivate the RCB18350 Compound.